• Patient Recruitment Rate [ Time Frame: 6 months ]
  Number of patients approached for inclusion will be compared to number who enrolled
• Estimated device use using total body surface area compared to actual device use measured by patient report [ Time Frame: 6 months ]
  Compliance of use/feasibility will be assessed by measuring estimated patient device use and comparing it to actual use as measured by returned tubes and notes on daily diary.
• Compliance with protocol [ Time Frame: 6 months ]
  Amount of cream estimated will be compared to patients' actual use as measured by number of tubes provided versus number of tubes used weekly
• Dermatology Life Quality Index [ Time Frame: 6 months ]
  The DLQI measures the impact of dermatological conditions on a patient's quality of life. The DLQI is scored by summing the score of each question (answered from not at all, 0, to very much, 3). The maximum is 30 and the minimum is 0. The higher the score, the greater the impairment of quality of life. Data will be aggregated across treatment groups.
• Radiation Therapy Oncology Group Skin Toxicity Scoring [ Time Frame: 6 months ]
  The RTOG will be used to track skin reactions to radiation therapy. No toxicity is considered a 0, while massive toxicity is considered a 4. Data will be aggregated across groups at each time point.

The primary objectives of the proposed research are to evaluate patient use of KeraStat Cream and collect data to inform a larger future trial.

The secondary objectives are to assess the safety and tolerability of KeraStat Cream in subjects at risk of radiation dermatitis, to assess the effectiveness of KeraStat Cream and how that compares to the current standard of care, and to estimate the amount of KeraStat Cream used per patient and coverage on skin.

• Device: KeraStat(R) Cream
  KeraStat Cream is a cream wound dressing that contains 5% keratin.
• Other: Standard of care
  Patients will be instructed to follow institutional standard of care for radiation dermatitis

• Standard of care
  Patients undergoing radiation therapy for breast cancer will be provided instructions for radiation dermatitis per institutional standard of care
  Intervention: Other: Standard of care
• Experimental: KeraStat Cream
  Patients undergoing radiation therapy for breast cancer will be provided KeraStat Cream for twice daily application.
  Intervention: Device: KeraStat(R) Cream

Inclusion Criteria:

1. Age 18 to 70
2. Female
3. Diagnosis of breast cancer and scheduled to receive 4 to 6 weeks of radiation therapy (radiation dose of 42 Gy or more)
4. Able and willing to sign protocol consent form
5. Able and willing to document symptoms and treatment details as often as needed, not to exceed daily notes
6. Able and willing to have photographs of the affected area taken regularly

Exclusion Criteria:

1. Women who are pregnant, lactating/nursing or plan to become pregnant
2. Previous radiation therapy to the area to be treated with radiation therapy
3. Receiving palliative radiation therapy
4. Unhealed or infected surgical sites in the irradiation area
5. Patients undergoing cytotoxic chemotherapy or concurrent Herceptin as part of overall treatment plan (tamoxifen/aromatase inhibitor allowed)
6. Use of oral corticosteroids or topical corticosteroids in the irradiation area
7. Autoimmune disease
8. Skin disease in target irradiation area
9. Known allergy to the standard of care or ingredients in KeraStat Cream